Compare MYGN & LION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYGN | LION |
|---|---|---|
| Founded | 1991 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.5M | 2.4B |
| IPO Year | 1995 | N/A |
| Metric | MYGN | LION |
|---|---|---|
| Price | $6.45 | $9.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $11.82 | $9.11 |
| AVG Volume (30 Days) | 910.3K | ★ 3.1M |
| Earning Date | 11-03-2025 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $825,300,000.00 | ★ $3,858,000,000.00 |
| Revenue This Year | $0.08 | N/A |
| Revenue Next Year | $5.28 | $22.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.21 | ★ 21.18 |
| 52 Week Low | $3.76 | $5.55 |
| 52 Week High | $15.47 | $9.41 |
| Indicator | MYGN | LION |
|---|---|---|
| Relative Strength Index (RSI) | 39.01 | 76.84 |
| Support Level | $6.38 | $8.21 |
| Resistance Level | $6.89 | $9.25 |
| Average True Range (ATR) | 0.29 | 0.43 |
| MACD | -0.06 | 0.09 |
| Stochastic Oscillator | 5.71 | 92.52 |
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.